A press release from insurer Anthem described its survey published in Benefits Quarterly, which found that 90% of large employers considered the cost of new specialty drugs a challenge. To explain this burden, it referenced a Payer Perspective article titled “The Growing Cost of Specialty Pharmacy: Is it Sustainable?” and published by AJMC® in 2013. This article discussed how the array of specialty drugs on the market had “grown substantially” from 10 in 1990 to nearly 300 in 2012.
There are 3 significant challenges providers face in implementing payments, according to an article on RevCycleIntelligence.com, including the unexpected spending that can arise as a result of complications or nonadherence. It illustrated this point with a quote from a 2016 AJMC® interview, “Dr Joshua Cohen Considers the Cons of Bundled Payments.” “There are situations where using a bundle may be inappropriate because the factors that are influencing differences in cost among patients are things that the provider doesn’t actually control,” Cohen said.